<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">543</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-3-52-59</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Endothelial dysfunction in patients with hereditary spherocytosis and b-thalassemia</article-title><trans-title-group xml:lang="ru"><trans-title>Дисфункция эндотелия у пациентов с наследственным сфероцитозом и b-талассемией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3650-0309</contrib-id><name-alternatives><name xml:lang="en"><surname>Chuyko</surname><given-names>Ya. M.</given-names></name><name xml:lang="ru"><surname>Чуйко</surname><given-names>Я. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7534-3863</contrib-id><name-alternatives><name xml:lang="en"><surname>Seregina</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Серёгина</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Elena A. Seregina</bold>, a Research Associate of the Laboratory of Clinical Hemostasis</p><p>1 Samory Mashela St., Moscow 117997 </p></bio><bio xml:lang="ru"><p><bold>Серёгина Елена Александровна</bold>, научный сотрудник лаборатории клинического гемостаза </p><p>117997, Москва, ул. Саморы Машела, 1 </p></bio><email>elsereg@inbox.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3491-1884</contrib-id><name-alternatives><name xml:lang="en"><surname>Vuimo</surname><given-names>T. A.</given-names></name><name xml:lang="ru"><surname>Вуймо</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5209-2099</contrib-id><name-alternatives><name xml:lang="en"><surname>Poletaev</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Полетаев</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8805-1499</contrib-id><name-alternatives><name xml:lang="en"><surname>Smetanina</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Сметанина</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Moscow</p></bio><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН Центр теоретических проблем физико-химической фармакологии РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-10-08" publication-format="electronic"><day>08</day><month>10</month><year>2021</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>52</fpage><lpage>59</lpage><history><date date-type="received" iso-8601-date="2021-10-07"><day>07</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-07"><day>07</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/543">https://hemoncim.com/jour/article/view/543</self-uri><abstract xml:lang="en"><p>Patients with hereditary spherocytosis and b-Thalassemia are characterized by the increased risk of thrombosis. The early manifestation of thrombotic complications can occur even in childhood especially after surgery. Hypercoagulability can be associated with endothelial dysfunction. The aim of this study was to investigate the hemostatic state and endothelial function in children with hereditary spherocytosis and b-thalassemia. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The hemostatic status of 18 children (10 boys and 8 girls from 1 to 13 years) with hereditary spherocytosis and of 8 children (4 boys and 4 girls from 3 to 8 years) with b-thalassemia was assessed using clotting times (activated partial thromboplastin time – APTT, thrombin time – TT, prothrombin time PT), fibrinogen levels and markers of endothelium dysfunction: endothelin-1 and thrombomodulin levels. Patients with hereditary spherocytosis were divided into 2 groups: during the hemolytic crisis (11 patients) and without the hemolytic crisis (7 patients). Patients with b-Thalassemia were divided into 3 groups: b-thalassemia major, b-thalassemia intermedia and b-thalassemia minor. APTT, TT and PT were not changed significantly between groups. We find the decreased fibrinogen levels in patients with severe condition: in hereditary spherocytosis patients during hemolytic crisis (1.9 ± 0.3 ng/ml with normal range 2–3.9 ng/ml) and in b-thalassemia major patients (1.8 ± 0.3 ng/ml with normal range 2–3.9 ng/ml). This could be caused by consumption of fibrinogen during acute hemolysis. The Thrombomodulin levels were increased in all hereditary spherocytosis patients, but median value was higher in group with hemolytic crisis (6665 pg/ml vs 5976 pg/ml with ormal value 275–909 pg/ml) indicating endothelium dysfunction and activation of blood clotting. In b-thalassemia patients Thrombomodulin levels were more elevated in b-thalassemia major and b-thalassemia intermedia (6389 ± 537 pg/ml и 6804 ± 120 pg/ml) compared to b-thalassemia minor (2727 ± 213 pg/ml) which is still higher than normal range. Endothelin-1 levels were elevated on 55% with hereditary spherocytosis patients during crisis vs 43% without. In general Endothelin-1 levels were more elevated in b-thalassemia patients (were normal in b-thalassemia minor) vs hereditary spherocytosis patients (2.33 ± 2.89 fmol/ml vs 0.95 ± 0.35 fmol/ml). Thrombomodulin and endothelin-1 levels revealed endothelium dysfunction in children with hemolysis. More dramatic changes observed in severe condition: in hereditary spherocytosis patients during hemolytic crisis and in b-thalassemia major and b-thalassemia intermedia patients.</p></abstract><trans-abstract xml:lang="ru"><p>Пациенты с наследственным сфероцитозом и b-талассемией характеризуются повышенным риском тромбоза по сравнению с общей популяцией. Развитие гиперкоагуляции может быть связано с эндотелиальной дисфункцией. Целью данного исследования является оценка состояния свертывания крови и эндотелия у детей с наследственным сфероцитозом и b-талассемией. Данное исследование одобрено независимым этическим комитетом и утверждено решением ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева. Состояние системы гемостаза у 18 детей с наследственным сфероцитозом (10 мальчиков и 8 девочек от 1 до 13 лет) и 8 детей с b-талассемией (4 мальчика и 4 девочки от 3 до 8 лет) оценивали с использованием стандартных времен свертывания (активированное частичное тромбопластиновое время – АЧТВ, тромбиновое время – ТВ, протромбиновый индекс – ПИ), концентрации фибриногена и маркеров дисфункции эндотелия: концентраций эндотелина-1 и тромбомодулина. Пациенты с наследственным сфероцитозом были разделены на 2 подгруппы: во время гемолитического кризиса (n = 11) и вне гемолитического кризиса (n = 7). Пациентов с b-талассемией разделили на 3 подгруппы в зависимости от тяжести заболевания: большая, промежуточная и малая формы. Значения АЧТВ, ТВ и ПИ не различались между подгруппами. Мы обнаружили снижение концентрации фибриногена у пациентов с тяжелым течением заболевания: во время гемолитического кризиса при наследственном сфероцитозе (1,9 ± 0,3 мг/мл при референтном диапазоне 2–3,9 мг/мл) и при большой форме b-талассемии (1,8 ± 0,3 мг/мл при референтном диапазоне 2–3,9 мг/мл). Это может быть вызвано потреблением фибриногена при активном гемолизе. Содержание тромбомодулина было повышено у всех пациентов с наследственным сфероцитозом, но медианное значение было выше у пациентов с кризом (6665 пг/мл против 5976 пг/мл при референтном диапазоне 275–909 пг/мл). У пациентов с b-талассемией содержание тромбомодулина было значительно повышено при большой и промежуточной формах (6389 ± 537 пг/мл и 6804 ± 120 пг/мл соответственно) по сравнению с малой формой (2727 ± 213 пг/мл). Однако и при малой форме b-талассемии концентрация тромбомодулина все еще была выше нормального диапазона. Концентрация эндотелина-1 была повышена у 55% пациентов с наследственным сфероцитозом во время кризиса и 43% больных вне криза. В целом содержание эндотелина-1 было значительнее повышено у пациентов с большой и промежуточной формами b-талассемии (при малой форме соответствовало референтным значениям) по сравнению с пациентами с наследственным сфероцитозом даже во время криза (2,33 ± 2,89 фмоль/мл и 0,95 ± 0,35 фмоль/мл соответственно). Содержание тромбомодулина и эндотелина-1 выявляет дисфункцию эндотелия у детей с гемолизом, что может быть одной из причин прокоагулянтного состояния. Более резкие изменения наблюдаются при большей интенсивности гемолиза: у пациентов с наследственным сфероцитозом во время гемолитического кризиса и у больных с большой и промежуточной формами b-талассемии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hemostasis</kwd><kwd>hereditary spherocytosis</kwd><kwd>b-thalassemia</kwd><kwd>endothelial dysfunction</kwd><kwd>children</kwd><kwd>thrombomodulin</kwd><kwd>endothelin-1</kwd><kwd>hemolysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гемостаз</kwd><kwd>наследственный сфероцитоз</kwd><kwd>b-талассемия</kwd><kwd>эндотелиальная дисфункция</kwd><kwd>дети</kwd><kwd>тромбомодулин</kwd><kwd>эндотелин-1</kwd><kwd>гемолиз</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Barker J.E., Wandersee N.J. Thrombosis in Heritable Hemolytic Disorders: Curr Opin Hematol 1999; 6 (2): 71. DOI: 10.1097/00062752-199903000-00003</mixed-citation><mixed-citation xml:lang="ru">Barker J.E., Wandersee N.J. Thrombosis in Heritable Hemolytic Disorders: Curr Opin Hematol 1999; 6 (2): 71. DOI: 10.1097/00062752-199903000-00003</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. McGrew W., Avant G.R. Hereditary Spherocytosis and Portal Vein Thrombosis. J Clin Gastroenterol 1984; 6 (4): 381–2.</mixed-citation><mixed-citation xml:lang="ru">McGrew W., Avant G.R. Hereditary Spherocytosis and Portal Vein Thrombosis. J Clin Gastroenterol 1984; 6 (4): 381–2.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Ezov N., Levin-Harrus T., Mittelman M., Redlich M., Shabat S., Ward S.M., et al. А Chemically Induced Rat Model of Hemolysis with Disseminated Thrombosis. Cardiovasc Toxicol 2002; 2 (3); 181–93. DOI: 10.1007/s12012-002-0003-6</mixed-citation><mixed-citation xml:lang="ru">Ezov N., Levin-Harrus T., Mittelman M., Redlich M., Shabat S., Ward S.M., et al. А Chemically Induced Rat Model of Hemolysis with Disseminated Thrombosis. Cardiovasc Toxicol 2002; 2 (3); 181–93. DOI: 10.1007/s12012-002-0003-6</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Ataga K.I. Hypercoagulability and Thrombotic Complications in Hemolytic Anemias. Haematologica 2009; 94 (11): 1481–4. DOI: 10.3324/haematol.2009.013672</mixed-citation><mixed-citation xml:lang="ru">Ataga K.I. Hypercoagulability and Thrombotic Complications in Hemolytic Anemias. Haematologica 2009; 94 (11): 1481–4. DOI: 10.3324/haematol.2009.013672</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Crary S.E., Troendle S., Ahmad N., Buchanan G.R. Traditional Laboratory Measures of Cardiovascular Risk in Hereditary Spherocytosis. Pediatr Blood Cancer 2010; 55 (4): 684–9. DOI: 10.1002/pbc.22640</mixed-citation><mixed-citation xml:lang="ru">Crary S.E., Troendle S., Ahmad N., Buchanan G.R. Traditional Laboratory Measures of Cardiovascular Risk in Hereditary Spherocytosis. Pediatr Blood Cancer 2010; 55 (4): 684–9. DOI: 10.1002/pbc.22640</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Taher A., Isma’eel H., Mehio G., Bignamini D., Kattamis A., Rachmilewitz E.A., et al. Prevalence of Thromboembolic Events among 8 860 Patients with Thalassaemia Major and Intermedia in the Mediterranean Area and Iran. Thromb Haemost 2006; 96 (4): 488–91.</mixed-citation><mixed-citation xml:lang="ru">Taher A., Isma’eel H., Mehio G., Bignamini D., Kattamis A., Rachmilewitz E.A., et al. Prevalence of Thromboembolic Events among 8 860 Patients with Thalassaemia Major and Intermedia in the Mediterranean Area and Iran. Thromb Haemost 2006; 96 (4): 488–91.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Bolton-Maggs P.H.B., Stevens R.F., Dodd N.J., Lamont G., Tittensor P., King M.-J. General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the Diagnosis and Management of Hereditary Spherocytosis. Br J Haematol 2004; 126 (4): 455–74. DOI: 10.1111/j.1365-2141.2004.05052.x</mixed-citation><mixed-citation xml:lang="ru">Bolton-Maggs P.H.B., Stevens R.F., Dodd N.J., Lamont G., Tittensor P., King M.-J. General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the Diagnosis and Management of Hereditary Spherocytosis. Br J Haematol 2004; 126 (4): 455–74. DOI: 10.1111/j.1365-2141.2004.05052.x</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Abdullah F., Zhang Y., Camp M., Rossberg M.I., Bathurst M.A., Colombani P.M., et al. Splenectomy in Hereditary Spherocytosis: Review of 1657 Patients and Application of the Pediatric Quality Indicators. Pediatr Blood Cancer 2009; 52 (7): 834–7. DOI: 10.1002/pbc.21954</mixed-citation><mixed-citation xml:lang="ru">Abdullah F., Zhang Y., Camp M., Rossberg M.I., Bathurst M.A., Colombani P.M., et al. Splenectomy in Hereditary Spherocytosis: Review of 1657 Patients and Application of the Pediatric Quality Indicators. Pediatr Blood Cancer 2009; 52 (7): 834–7. DOI: 10.1002/pbc.21954</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Ataga K.I., Cappellini M.D., Rachmilewitz E.A. b-Thalassaemia and Sickle Cell Anaemia as Paradigms of Hypercoagulability. Br J Haematol 2007; 139 (1): 3–13. DOI: 10.1111/j.1365-2141.2007.06740.x</mixed-citation><mixed-citation xml:lang="ru">Ataga K.I., Cappellini M.D., Rachmilewitz E.A. b-Thalassaemia and Sickle Cell Anaemia as Paradigms of Hypercoagulability. Br J Haematol 2007; 139 (1): 3–13. DOI: 10.1111/j.1365-2141.2007.06740.x</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Cappellini M.D., Poggiali E., Taher A.T., Musallam K.M. Hypercoagulability in b-Thalassemia: A Status Quo. Expert Rev Hematol 2012; 5 (5): 505–11, quiz 512. DOI: 10.1586/ehm.12.42</mixed-citation><mixed-citation xml:lang="ru">Cappellini M.D., Poggiali E., Taher A.T., Musallam K.M. Hypercoagulability in b-Thalassemia: A Status Quo. Expert Rev Hematol 2012; 5 (5): 505–11, quiz 512. DOI: 10.1586/ehm.12.42</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Borenstain-Ben Yashar V., Barenholz Y., Hy-Am E., Rachmilewitz E.A., Eldor A. Phosphatidylserine in the Outer Leaflet of Red Blood Cells from Beta-Thalassemia Patients May Explain the Chronic Hypercoagulable State and Thrombotic Episodes. Am J Hematol 1993; 44 (1): 63–5. DOI: 10.1002/ajh.2830440114</mixed-citation><mixed-citation xml:lang="ru">Borenstain-Ben Yashar V., Barenholz Y., Hy-Am E., Rachmilewitz E.A., Eldor A. Phosphatidylserine in the Outer Leaflet of Red Blood Cells from Beta-Thalassemia Patients May Explain the Chronic Hypercoagulable State and Thrombotic Episodes. Am J Hematol 1993; 44 (1): 63–5. DOI: 10.1002/ajh.2830440114</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Panigrahi I., Agarwal S. Thromboembolic Complications in Beta-Thalassemia: Beyond the Horizon. Thromb Res 2007; 120 (6): 783–9. DOI: 10.1016/j.thromres.2007.01.015</mixed-citation><mixed-citation xml:lang="ru">Panigrahi I., Agarwal S. Thromboembolic Complications in Beta-Thalassemia: Beyond the Horizon. Thromb Res 2007; 120 (6): 783–9. DOI: 10.1016/j.thromres.2007.01.015</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Habib A., Kunzelmann C., Shamseddeen W., Zobairi F., Freyssinet J.-M., Taher A. Elevated Levels of Circulating Procoagulant Microparticles in Patients with Beta-Thalassemia Intermedia. Haematologica 2008; 93 (6): 941–2. DOI: 10.3324/haematol.12460</mixed-citation><mixed-citation xml:lang="ru">Habib A., Kunzelmann C., Shamseddeen W., Zobairi F., Freyssinet J.-M., Taher A. Elevated Levels of Circulating Procoagulant Microparticles in Patients with Beta-Thalassemia Intermedia. Haematologica 2008; 93 (6): 941–2. DOI: 10.3324/haematol.12460</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Eldor A., Durst R., Hy-Am E., Goldfarb A., Gillis S., Rachmilewitz E.A., et al. A Chronic Hypercoagulable State in Patients with Beta-Thalassaemia Major Is Already Present in Childhood. Br J Haematol 1999; 107 (4): 739–46. DOI: 10.1046/j.1365-2141.1999.01758.x</mixed-citation><mixed-citation xml:lang="ru">Eldor A., Durst R., Hy-Am E., Goldfarb A., Gillis S., Rachmilewitz E.A., et al. A Chronic Hypercoagulable State in Patients with Beta-Thalassaemia Major Is Already Present in Childhood. Br J Haematol 1999; 107 (4): 739–46. DOI: 10.1046/j.1365-2141.1999.01758.x</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Mullier F., Lainey E., Fenneteau O., Da Costa L., Schillinger F., Bailly N., et al. Additional Erythrocytic and Reticulocytic Parameters Helpful for Diagnosis of Hereditary Spherocytosis: Results of a Multicentre Study. Ann Hematol 2011; 90 (7): 759–68. DOI: 10.1007/s00277-010-1138-3</mixed-citation><mixed-citation xml:lang="ru">Mullier F., Lainey E., Fenneteau O., Da Costa L., Schillinger F., Bailly N., et al. Additional Erythrocytic and Reticulocytic Parameters Helpful for Diagnosis of Hereditary Spherocytosis: Results of a Multicentre Study. Ann Hematol 2011; 90 (7): 759–68. DOI: 10.1007/s00277-010-1138-3</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Wagner G.M., Chiu D.T., Yee M.C., Lubin B.H. Red Cell Vesiculation – a Common Membrane Physiologic Event. J Lab Clin Med 1986; 108 (4): 315–24.</mixed-citation><mixed-citation xml:lang="ru">Wagner G.M., Chiu D.T., Yee M.C., Lubin B.H. Red Cell Vesiculation – a Common Membrane Physiologic Event. J Lab Clin Med 1986; 108 (4): 315–24.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Troendle S.B., Adix L., Crary S.E., Buchanan G.R. Laboratory Markers of Thrombosis Risk in Children with Hereditary Spherocytosis. Pediatr Blood Cancer 2007; 49 (6): 781–5. DOI: 10.1002/pbc.21319</mixed-citation><mixed-citation xml:lang="ru">Troendle S.B., Adix L., Crary S.E., Buchanan G.R. Laboratory Markers of Thrombosis Risk in Children with Hereditary Spherocytosis. Pediatr Blood Cancer 2007; 49 (6): 781–5. DOI: 10.1002/pbc.21319</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Gelas T., Scalabre A., Hameury F., Dubois R., Grosos C., Mouriquand P.D., et al. Portal Vein Thrombosis after Laparoscopic Splenectomy during Childhood. J Thromb Thrombolysis 2014; 38 (2): 218–22. DOI: 10.1007/s11239-013-1037-2</mixed-citation><mixed-citation xml:lang="ru">Gelas T., Scalabre A., Hameury F., Dubois R., Grosos C., Mouriquand P.D., et al. Portal Vein Thrombosis after Laparoscopic Splenectomy during Childhood. J Thromb Thrombolysis 2014; 38 (2): 218–22. DOI: 10.1007/s11239-013-1037-2</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Das A., Bansal D., Ahluwalia J., Das R., Rohit M. K., Attri S.V., et al. Risk Factors for Thromboembolism and Pulmonary Artery Hypertension Following Splenectomy in Children with Hereditary Spherocytosis. Pediatr Blood Cancer 2014; 61 (1): 29–33. DOI: 10.1002/pbc.24766</mixed-citation><mixed-citation xml:lang="ru">Das A., Bansal D., Ahluwalia J., Das R., Rohit M. K., Attri S.V., et al. Risk Factors for Thromboembolism and Pulmonary Artery Hypertension Following Splenectomy in Children with Hereditary Spherocytosis. Pediatr Blood Cancer 2014; 61 (1): 29–33. DOI: 10.1002/pbc.24766</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Haybar H., Shahrabi S., Rezaeeyan H., Shirzad R., Saki N. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease. Cardiovasc Toxicol 2019; 19 (1): 13–22. DOI: 10.1007/s12012-018-9493-8</mixed-citation><mixed-citation xml:lang="ru">Haybar H., Shahrabi S., Rezaeeyan H., Shirzad R., Saki N. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease. Cardiovasc Toxicol 2019; 19 (1): 13–22. DOI: 10.1007/s12012-018-9493-8</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Özdemir Z.C., Kar Y.D., Gündüz E., Bör Ö. Evaluation of the Coagulation Profile With Rotational Thromboelastometry in Children With Hereditary Spherocytosis. J Pediatr Hematol Oncol 2020; 42 (4): e195–8. DOI: 10.1097/MPH.0000000000001702</mixed-citation><mixed-citation xml:lang="ru">Özdemir Z.C., Kar Y.D., Gündüz E., Bör Ö. Evaluation of the Coagulation Profile With Rotational Thromboelastometry in Children With Hereditary Spherocytosis. J Pediatr Hematol Oncol 2020; 42 (4): e195–8. DOI: 10.1097/MPH.0000000000001702</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Seregina E.A., Poletaev A.V., Bondar E.V., Vuimo T.A., Ataullakhanov F.I., Smetanina N.S. The Hemostasis System in Children with Hereditary Spherocytosis. Thromb Res 2019; 176: 11–7. DOI: 10.1016/j.thromres.2019.02.004</mixed-citation><mixed-citation xml:lang="ru">Seregina E.A., Poletaev A.V., Bondar E.V., Vuimo T.A., Ataullakhanov F.I., Smetanina N.S. The Hemostasis System in Children with Hereditary Spherocytosis. Thromb Res 2019; 176: 11–7. DOI: 10.1016/j.thromres.2019.02.004</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Сметанина Н.С., Масчан А.А., Кузьминова Ж.А., Луговская С.А. Клинические рекомендации. Детская гематология. Под ред. Румянцева А.Г., Масчана А.А., Жуковской Е.В. М.: ГЭОТАР-Медиа; 2015. С. 145–59.</mixed-citation><mixed-citation xml:lang="ru">Сметанина Н.С., Масчан А.А., Кузьминова Ж.А., Луговская С.А. Клинические рекомендации. Детская гематология. Под ред. Румянцева А.Г., Масчана А.А., Жуковской Е.В. М.: ГЭОТАР-Медиа; 2015. С. 145–59.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Nasimuzzaman M., Arumugam P.I., Mullins E.S., James J.M., Vanden Heuvel K., Narciso M.G., et al. Elimination of the Fibrinogen Integrin AMb2-Binding Motif Improves Renal Pathology in Mice with Sickle Cell Anemia. Blood Adv 2019; 3 (9): 1519–32. DOI: 10.1182/bloodadvances.2019032342</mixed-citation><mixed-citation xml:lang="ru">Nasimuzzaman M., Arumugam P.I., Mullins E.S., James J.M., Vanden Heuvel K., Narciso M.G., et al. Elimination of the Fibrinogen Integrin AMb2-Binding Motif Improves Renal Pathology in Mice with Sickle Cell Anemia. Blood Adv 2019; 3 (9): 1519–32. DOI: 10.1182/bloodadvances.2019032342</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Favaloro E.J., (Adcock) Funk D.M., Lippi G. Pre-Analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis. Lab Med 2012; 43 (2): 1.2–10. DOI: 10.1309/LM749BQETKYPYPVM</mixed-citation><mixed-citation xml:lang="ru">Favaloro E.J., (Adcock) Funk D.M., Lippi G. Pre-Analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis. Lab Med 2012; 43 (2): 1.2–10. DOI: 10.1309/LM749BQETKYPYPVM</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Постникова Л.Б., Кубышева Н.И., Миндубаев Р.З., Болдина М.В., Соодаева С.К. Особенности содержания эндотелина-1 и эндобронхиальной концентрации метаболитов оксида азота при хронической обструктивной болезни легких. Пульмонология 2010; 3: 108–12.</mixed-citation><mixed-citation xml:lang="ru">Постникова Л.Б., Кубышева Н.И., Миндубаев Р.З., Болдина М.В., Соодаева С.К. Особенности содержания эндотелина-1 и эндобронхиальной концентрации метаболитов оксида азота при хронической обструктивной болезни легких. Пульмонология 2010; 3: 108–12.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Frei A.C., Guo Y., Jones D.W., Pritchard K.A., Fagan K.A., Hogg N., et al. Vascular Dysfunction in a Murine Model of Severe Hemolysis. Blood 2008; 112 (2): 398–405. DOI: 10.1182/blood-2007-12-126714</mixed-citation><mixed-citation xml:lang="ru">Frei A.C., Guo Y., Jones D.W., Pritchard K.A., Fagan K.A., Hogg N., et al. Vascular Dysfunction in a Murine Model of Severe Hemolysis. Blood 2008; 112 (2): 398–405. DOI: 10.1182/blood-2007-12-126714</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Iolascon A., Andolfo I., Barcellini W., Corcione F., Garçon L., De Franceschi L., et al. Recommendations Regarding Splenectomy in Hereditary Hemolytic Anemias. Haematologica 2017; 102 (8): 1304–13. DOI: 10.3324/haematol.2016.161166</mixed-citation><mixed-citation xml:lang="ru">Iolascon A., Andolfo I., Barcellini W., Corcione F., Garçon L., De Franceschi L., et al. Recommendations Regarding Splenectomy in Hereditary Hemolytic Anemias. Haematologica 2017; 102 (8): 1304–13. DOI: 10.3324/haematol.2016.161166</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Alexakis N., Dardamanis D., Albanopoulos K., Ptohis N., Skalistira M., Karagiorga M., et al. Incidence Risk Factors and Outcome of Portal Vein Thrombosis After Laparoscopic-Assisted Splenectomy in b-Thalassemia Patients: A Prospective Exploratory Study. J Laparoendosc Adv Surg Tech 2013; 23 (2): 123–8. DOI: 10.1089/lap.2012.0268</mixed-citation><mixed-citation xml:lang="ru">Alexakis N., Dardamanis D., Albanopoulos K., Ptohis N., Skalistira M., Karagiorga M., et al. Incidence Risk Factors and Outcome of Portal Vein Thrombosis After Laparoscopic-Assisted Splenectomy in b-Thalassemia Patients: A Prospective Exploratory Study. J Laparoendosc Adv Surg Tech 2013; 23 (2): 123–8. DOI: 10.1089/lap.2012.0268</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Satitthummanid S., Uaprasert N., Songmuang S.B., Rojnuckarin P., Tosukhowong P., Sutcharitchan P., et al. Depleted Nitric Oxide and Prostaglandin E2 Levels Are Correlated with Endothelial Dysfunction in b-Thalassemia/HbE Patients. Int J Hematol 2017; 106 (3): 366–74. DOI: 10.1007/s12185-017-2247-8</mixed-citation><mixed-citation xml:lang="ru">Satitthummanid S., Uaprasert N., Songmuang S.B., Rojnuckarin P., Tosukhowong P., Sutcharitchan P., et al. Depleted Nitric Oxide and Prostaglandin E2 Levels Are Correlated with Endothelial Dysfunction in b-Thalassemia/HbE Patients. Int J Hematol 2017; 106 (3): 366–74. DOI: 10.1007/s12185-017-2247-8</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Gursel O., Tapan S., Sertoglu E., Taşçılar E., Eker I., Ileri T., et al. Elevated Plasma Asymmetric Dimethylarginine Levels in Children with Beta-Thalassemia Major May Be an Early Marker for Endothelial Dysfunction. Haematology 2018; 23 (5): 304–8. DOI: 10.1080/10245332.2017.1396027</mixed-citation><mixed-citation xml:lang="ru">Gursel O., Tapan S., Sertoglu E., Taşçılar E., Eker I., Ileri T., et al. Elevated Plasma Asymmetric Dimethylarginine Levels in Children with Beta-Thalassemia Major May Be an Early Marker for Endothelial Dysfunction. Haematology 2018; 23 (5): 304–8. DOI: 10.1080/10245332.2017.1396027</mixed-citation></citation-alternatives></ref></ref-list></back></article>
